Skip to main content
. 2021 Jun 13;42(25):2455–2467. doi: 10.1093/eurheartj/ehab312

Figure 2.

Figure 2

External validation of SCORE2-OP for (A) the estimation of risk for myocardial infarction, stroke, or cardiovascular disease mortality (primary endpoint) and (B) the estimation of risk for myocardial infarction, stroke, hospitalization for heart failure, or cardiovascular disease mortality (cardiovascular disease events including heart failure). Trial populations: HYVET, PROSPER, and SPRINT.